#283 ‒ Gut health & the microbiome: improving and maintaining the microbiome, probiotics, prebiotics, innovative treatments, and more | Colleen Cutcliffe, Ph.D.

Episode Summary

Executive Summary: Peter Atiyah and Colleen Cutcliffe explore the microbiome as a mutable, measurable ecosystem that may influence metabolism, cravings, and disease risk. They contrast hype with evidence, explain how probiotics/prebiotics/postbiotics differ, and focus on Pendulum’s work with Akkermansia and fiber-feeding strains to raise GLP-1 and improve glucose control. The discussion emphasizes rigorous manufacturing, clinical trials, and the promise of microbiome-based interventions beyond diet alone.

Main Topics: Defining the microbiome and how it develops (Priority: 5/5): The microbiome is described as the collection of microbes on and in the body, seeded at birth and shaped by diet, environment, and aging. Diversity rises through childhood and peaks in adolescence before declining later in life. Why microbiome science is hard to study (Priority: 5/5): Cutcliffe explains strain-level variability, the limits of one-time population snapshots, the need for longitudinal sampling, and the difficulty of measuring gut contents without contamination. Microbial function: fiber, short-chain fatty acids, and butyrate (Priority: 5/5): The conversation centers on how gut microbes metabolize insoluble fiber into short-chain fatty acids, especially butyrate, which supports colon health and may stimulate GLP-1 release. C. difficile and fecal microbiome transplantation (Priority: 4/5): C. diff is used as the clearest example of microbiome manipulation affecting disease, with fecal transplants framed as highly effective but messy and difficult to standardize. Akkermansia and Pendulum’s product strategy (Priority: 5/5): Akkermansia muciniphila is presented as a key strain linked to metabolic health, GLP-1 signaling, mucin-layer support, and improved glucose control; Pendulum’s products are built around this biology. Clinical evidence and product development (Priority: 4/5): The discussion reviews Pendulum’s randomized trial in type 2 diabetes, the challenges of manufacturing strict anaerobes, and the company’s move from a high-cost premium product to broader consumer offerings. Consumer use, probiotics, and regulation (Priority: 4/5): They discuss CFUs vs active fraction units, refrigeration, shelf stability, GRAS vs IND pathways, and the gap between marketing claims and real evidence in the supplement market.

Key Arguments: The microbiome is not just a collection of bacteria; it is a functional ecosystem whose outputs matter more than its taxonomy alone. Microbiome composition is highly individualized and changes rapidly with diet, antibiotics, travel, stress, and circadian disruption. Longitudinal and functional measurements are more informative than one-time sequencing snapshots because microbes replicate and evolve quickly. Fiber is a key prebiotic because it feeds microbial fermentation pathways that generate butyrate and other metabolites relevant to gut and metabolic health. Akkermansia appears to be a keystone strain associated with metabolic health, lower obesity risk, and better response to dietary interventions. Pendulum’s approach is to combine strains that work together, rather than rely on a single organism, to improve reproducibility and efficacy. Fecal microbiome transplant proves the microbiome can alter physiology, but its variability and safety issues make it hard to standardize as a therapy. Microbiome-based products may sit between nutrition and drugs: more biologically grounded than supplements, but less invasive than pharmaceuticals. Consumer probiotics are often poorly characterized; CFU counts can be misleading because they do not capture viability, dead cells, or functional output. The gut may influence cravings, satiety, and glucose control through GLP-1 and other signaling molecules, suggesting a gut-brain-metabolism axis.

Data Points: Peak microbiome diversity: Teenage years - Cutcliffe said diversity is highest when people can eat almost anything without consequence. Human Microbiome Project sample size: 10,000+ people - Used as an early population snapshot of microbiome variation across body sites. Microbiome-to-human cell ratio: Often cited as 10:1, but questioned - Atiayah and Cutcliffe noted the exact ratio is less important than the large functional burden microbes carry. Bacterial replication time: As fast as 10 to 15 minutes - Used to explain rapid microbial evolution and antibiotic resistance. Microbiome study cost: $5,000 to $6,000 per sample - Approximate cost for longitudinal, functional microbiome analysis described by Cutcliffe. Shotgun sequencing cost: Several thousand dollars per sample - Needed to comprehensively identify microbial genomes and functions. Akkermansia abundance in healthy people: About 5% to 10% - Cutcliffe said healthy individuals often show this range, though exact prevalence varies. Recommended fiber intake: Roughly 20 to 30 grams/day - Discussed as a common target, though average intake is far lower. Average American fiber intake: About 1 to 2 grams/day - Used to illustrate how far typical intake falls below recommended levels. Pendulum clinical trial size: 76 participants - Pilot randomized, placebo-controlled trial in people with type 2 diabetes. Trial duration: 90 days - Intervention period for the five-strain formulation study. A1C reduction: 0.6 percentage points vs placebo - Reported improvement in the full five-strain arm over 90 days. Blood glucose spike reduction: 34% - Area-under-the-curve reduction in oral glucose tolerance testing in the full formulation arm. A1C range at baseline: About 7.5 to 8.2 - Approximate starting range for participants in the diabetes trial. Company funding raised: $150 million - Cutcliffe described the capital required to build manufacturing and run studies. Manufacturing plant cost: $10 million - Cost to build Pendulum’s anaerobic manufacturing facility. Product price: $165/month - Initial price of Pendulum Glucose Control. Lower-cost product price: $49/month - Price of Metabolic Daily, a lower-dose version of the five-strain product. Pure Akkermansia launch inventory: 1,000 bottles sold in under 10 days - Market test for a single-strain product. Clinical trial compliance: 100% stool-sample compliance - Participants provided multiple frozen stool samples during the study. Post-washout persistence: 15% to 20% - Share of participants who maintained Akkermansia levels after stopping the product for 30 days. FMT success rate: About 99% - Used as the strongest proof that microbiome manipulation can treat C. difficile infection. Antibiotic treatment success for C. diff: About 70% - Illustrated why fecal transplant can be preferable in recurrent or severe cases.

Pivotal Quotes: "“The microbiome is essentially all of the microbes... that reside in and on us.”" — Colleen Cutcliffe: Definition of the microbiome early in the conversation. "“When you take an antibiotic, that's essentially almost like a nuclear bomb to your microbiome.”" — Colleen Cutcliffe: Explaining how antibiotics can disrupt microbial ecosystems and enable C. difficile overgrowth. "“The microbiome has been a black box. And now we've got some tools here.”" — Peter Atiyah: Summarizing the episode’s central thesis about emerging microbiome interventions.

Implications: The episode suggests microbiome therapies may become a credible middle ground between diet and drugs, but only if products are standardized, mechanistically grounded, and validated in rigorous human trials. It also highlights how much remains unknown about strain-level causality and personalization.